Tbio CD84 SLAM family member 5

Protein Summary

Description

Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. Activities are controlled by presence or absence of small cytoplasmic adapter proteins, SH2D1A/SAP and/or SH2D1B/EAT-2. Can mediate natural killer (NK) cell cytotoxicity dependent on SH2D1A and SH2D1B (By similarity). Increases proliferative responses of activated T-cells and SH2D1A/SAP does not seem be required for this process. Homophilic interactions enhance interferon gamma/IFNG secretion in lymphocytes and induce platelet stimulation via a SH2D1A-dependent pathway. May serve as a marker for hematopoietic progenitor cells (PubMed:11564780, PubMed:12115647. PubMed:12928397, PubMed:12962726, PubMed:16037392) Required for a prolonged T-cell:B-cell contact, optimal T follicular helper function, and germinal center formation. In germinal centers involved in maintaining B-cell tolerance and in preventing autoimmunity (By similarity). In mast cells negatively regulates high affinity immunoglobulin epsilon receptor signaling; independent of SH2D1A and SH2D1B but implicating FES and PTPN6/SHP-1 (PubMed:22068234). In macrophages enhances LPS-induced MAPK phosphorylation and NF-kappaB activation and modulates LPS-induced cytokine secretion; involving ITSM 2 (By similarity). Positively regulates macroautophagy in primary dendritic cells via stabilization of IRF8; inhibits TRIM21-mediated proteasomal degradation of IRF8 (PubMed:29434592). This gene encodes a membrane glycoprotein that is a member of the signaling lymphocyte activation molecule (SLAM) family. This family forms a subset of the larger CD2 cell-surface receptor Ig superfamily. The encoded protein is a homophilic adhesion molecule that is expressed in numerous immune cells types and is involved in regulating receptor-mediated signaling in those cells. Alternate splicing results in multiple transcript variants. [provided by RefSeq, Oct 2011]

Uniprot Accession IDs

• Q9UIB8
• B2R8T1
• B7Z3R8
• O15430
• O95266
• O95660
• Q5H9R1
• Q6FHA8
• Q8WLP1
• Q8WWI8
• Q9UF04
• Q9UIB6
• Q9UIB7
• Q9UIT7

Gene Name

• CD84

Ensembl ID

• ENST00000311224
• ENSP00000312367
• ENSG00000066294
• ENST00000368048
• ENSP00000357027
• ENST00000368051
• ENSP00000357030
• ENST00000368054
• ENSP00000357033
• ENST00000534968
• ENSP00000442845

Symbol

• SLAMF5
• LY9B
• hCD84
• mCD84
• SLAMF5

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
transcription factor perturbation	0.88
tissue sample	0.71
microRNA	0.7
tissue	0.68
virus perturbation	0.68

Protein Classes

PANTHER Classes

Protein / Transferase / Kinase / Protein Kinase / Slam Family Member 5

Protein / Signaling Molecule / Membrane-bound Signaling Molecule / Slam Family Member 5

Protein / Receptor / Cytokine Receptor / Immunoglobulin Receptor Superfamily / Slam Family Member 5

Protein / Defense/immunity Protein / Immunoglobulin Receptor Superfamily / Slam Family Member 5

Protein / Cell Adhesion Molecule / Slam Family Member 5

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 45.19   (req: < 5)

Gene RIFs: 12   (req: <= 3)

Antibodies: 689   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 45.19   (req: >= 5)

Gene RIFs: 12   (req: > 3)

Antibodies: 689   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 12

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligand: 0

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 0